Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2019 Earnings Results

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.3%

Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which pleased investors and led to a slight increase in stock price. The lack of revenue data and guidance indicates uncertainty about future performance. However, the positive EPS surprise suggests that the company is managing its costs effectively.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.98	N/A	+5.57%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management remains cautiously optimistic about the company's future. They emphasized their commitment to innovation and growth.

Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.

They highlighted ongoing efforts to advance their pipeline.

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.3%

Key numbers

Management commentary

Alnylam Pharmaceuticals, Inc.

More earnings this week

Alnylam Pharmaceuticals Beats on EPS, Stock Up 0.3%

Key numbers

Management commentary